首页工具

JAK3-IN-11

产品编号 T9811 CAS 2412734-00-8

JAK3- in -11 (Compound 12) 是表现出强效的、无细胞毒性、不可逆、口服活性的JAK3抑制活性，IC50值为1.7 nM，具有出色的选择性(高于其他 JAK3 亚型的588倍)，共价结合到 JAK3 的 ATP-binding pocket。 JAK3-IN-11 强烈抑制 JAK3 依赖的信号转导和T 细胞增殖，是研究自身免疫性疾病的有效工具。

TargetMol的所有产品和服务仅用于科学研究，不能被用于人体，我们也不向个人提供产品和服务。

JAK3-IN-11, CAS 2412734-00-8

规格	价格/CNY	货期
25 mg	￥ 10,600	10-14周
50 mg	￥ 13,800	10-14周
100 mg	￥ 17,500	10-14周

大包装超大折扣，点击咨询

该分子属于定制产品。陶术拥有优秀的合成团队，经验和能力，可以为您提供高性价比的产品。但由于客观因素，研发中会存在小概率合成不成功的情况，还请理解，如您有任何问题，欢迎咨询，我们将竭诚为您服务。

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

产品描述	JAK3-IN-11 (Compound 12) exhibits potent, noncytotoxic, irreversible, orally active JAK3 inhibitory activity (IC50 = 1.7 nM) with an excellent selectivity profile (>588-fold compared to other JAK isoforms), covalently binds to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T-cell proliferation which is a promising tool for studying autoimmune diseases [1].
体外活性	JAK3-IN-11 (Compound 12) (10 μM, 72 h) has no obvious cytotoxicity at a concentration of 10 μM [1]. JAK3-IN-11 (Compound 12) (72 h) shows strong inhibition for T cell proliferation with IC 50 values of 0.83 μM (anti-CD3/CD28 stimulation) and 0.77 μM (IL-2 stimulation) [1]. JAK3-IN-11 (Compound 12) (0-10 μM, 1h) abrogates IL-2 or IL-15-induced phosphorylation of STAT5 in a concentration-dependent manner [1]. JAK3-IN-11 (Compound 12) covalently binds to JAK3 and irreversibly inhibits JAK3 [1]. Cell Proliferation Assay [1] Cell Line: Mouse T cells in complete RPMI1640 medium then exposed to anti-CD3/anti-CD28 or IL-2. Concentration: Incubation Time: 72 h. Result: Displayed strong inhibition for T cell proliferation with an IC 50 values of 0.83 μM (anti-CD3/CD28 stimulation) and 0.77 μM (IL-2 stimulation), showed obvious significant immunosuppressive activity under selective inhibition of JAK3. Western Blot Analysis [1] Cell Line: Purified T cells were pre-activated coated with anti-CD3 and anti-CD28 for 72 h, then cultured with IL-2 (50 U/mL) for 36 h, then, cultured without IL-2 for 36 h Concentration: 0.01, 0.1, 1, 10 μM. Incubation Time: 1 h. Result: Abrogated IL-2 or IL-15-induced phosphorylation of STAT5 in a concentration-dependent manner.
体内活性	JAK3-IN-11 (Compound 12) (Oxazolone (OXZ)-induced DTH Balb/c mice; 0-30 mg/kg; PO, prior to and during the challenge phase, 6 days) inhibits oxazolone (OXZ)-induced delayed type hypersensitivity (DTH) responses in a dose-dependent manner [1]. Animal Model: Oxazolone (OXZ)-induced DTH Balb/c mice model [1]. Dosage: 30, 10, and 3 mg/kg. Administration: PO, prior to and during the challenge phase, 6 days. Result: Dose-dependently inhibited oxazolone (OXZ)-induced delayed-type hypersensitivity (DTH) responses. Animal Model: Male ICR mice [1]. Dosage: 30 mg/kg for oral gavage, 10 mg/kg for intravenous administration. Administration: Pharmacokinetic Analysis Result: Preliminary pharmacokinetic data of JAK3-IN-11 (Compound 12) in male ICR Mice [1] Male ICR mice, 30 mg/kg for oral gavage, 10 mg/kg for intravenous administration [1]. Compound 12 iv (10 mg/kg) po (30 mg/kg) AUC(0-t) (mg/Lh) a 1244.41 ± 77.83 889.42 ± 48.32 AUC(0-∞) (mg/Lh) 1274.41 ± 57.18 897.12 ± 56.72 MRT (0-∞) (h) b 0.73 ± 0.08 1.42 ± 0.38 Vz (L/kg) c 8.36 ± 1.83 220.42 ± 24.71 CLz (L/h/kg) d 8.15 ± 1.21 97.14 ± 20.87 t 1/2 (h) e 0.47 ± 0.06 1.52 ± 0.34 C max (mg/L) f 8763.23 ± 324.65 2008.21 ± 189.44 Bioavailability(%) g 23.82% a Area under the concentration time curve. b Mean residence time. c Volume in steady state. d Plasma clearance. e Terminal half-life. f Peak plasma concentrations. g Bioavailability = AUC 0-t (po)/AUC 0-t × 100%.

分子量	401.46
分子式	C23H23N5O2
CAS No.	2412734-00-8

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +